Meridian Corporation has been rated a Sell by Crimson And Gold Research due to ongoing asset quality problems, declining earnings, and weak non-interest income. The company missed earnings expectations for three straight quarters, with Q3 2026 EPS at $0.43, below estimates and previous results. Nonperforming loans remain high at 3.55%, far exceeding the credit loss allowance of 0.96%, raising concerns about further financial deterioration. Despite a valuation below tangible book value, risks from concentrated commercial real estate exposure in Philadelphia and potential book value erosion make the stock unattractive for investors.
Meridian Corporation is the subject, here is Pluang's Financials sector snapshot as of Nov 06, 2026 19:11 WIB: Among 142 priced Financials stocks, 54 rose and 81 fell. Notable movers include HUT at USD 50.75 with a 10.45% gain and 58% buy orders, GLXY at USD 14.16 up 9.09% with 100% buy orders, and WULF at USD 10.84 rising 7.54% but with 76% sell orders. Typical hold times range from 7 to 22 days on Pluang.
Kendal Nutricare Limited will be referred to government and state agencies after refusing to participate in a compliance inquiry by the BBB National Programs’ National Advertising Division. The inquiry followed a challenge by Abbott Laboratories rega...
The Mexico animal healthcare market is projected to grow from $2.13 billion in 2025 to $3.34 billion by 2031, at a CAGR of 7.84%. Growth is fueled by rising spending on companion animals, expanding livestock production, and innovations in veterinary ...
Rainforest Distribution Corp. has implemented Samsara Route Planning and Commercial Navigation across its direct-store-delivery fleet, unifying routing, navigation, telematics, and compliance on one platform integrated with its SAP system. This upgra...
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
